What are the implications for research, policy, or practice?
CKD patients on haemodialysis should be screened for early detection of hearing loss. Larger prospective studies are needed to establish whether instituting haemodialysis would slow down progression of hearing loss in such patients.
Background
The incidence of chronic kidney disease (CKD) has increased significantly in the past few years, thanks to the huge rise in the number of people suffering from diabetes mellitus and systemic hypertension, which are major risk factors for CKD. Association of CKD with sensorineural hearing loss has been described by several studies in the past, although the basis for this has not been clearly established. 1, 2 Antigenic similarity between basement membranes of glomeruli and stria vascularis of the inner ear may explain this association to some extent. 3 Use of ototoxic drugs, electrolyte disturbances, and hypertension have been implicated in various studies. [4] [5] [6] Haemodialysis has also been reported to contribute to hearing loss in CKD. 7 Studies on the impact of haemodialysis have produced contradictory results, with a sizeable number reporting that haemodialysis plays no role in hearing loss associated with CKD. Although chronicity of disease was found to have no association with hearing loss in many studies, 8 a recent study demonstrated that the greater the duration of disease, the greater the hearing loss. 9 Thus, despite the multitude of studies regarding hearing loss in CKD, unanswered questions remain regarding the role of haemodialysis and duration of disease. We aimed to determine the prevalence and degree of hearing loss in CKD patients on haemodialysis, and to identify the association between hearing loss and factors like duration of CKD and number of haemodialysis sessions.
Method
This was a hospital-based case control study conducted in a tertiary care teaching hospital. The study comprised 120 adult patients with CKD, who have undergone at least one session of haemodialysis; 120 age and sex-matched controls were also enrolled. We excluded CKD patients with conductive hearing loss and syndromic etiologies of CKD in which hearing loss is a known component. All patients were interviewed using a uniform proforma containing information on age, gender, and risk factors, including diabetes, hypertension, and history of ototoxic drug use. Time since diagnosis of chronic kidney disease and number of haemodialysis sessions were documented. Blood parameters, including haemoglobin, blood urea, serum creatinine, sodium, potassium, chloride, and bicarbonate were also obtained.
All CKD patients and controls were subjected to hearing assessment using standard pure tone audiometry and impedance audiometry. Prevalence and degree of hearing loss was determined in CKD patients and controls. The patients with CKD on haemodialysis were further divided into two groups based on presence or absence of hearing loss. These two groups were compared for any differences with regard to exposure to ototoxic drugs, duration of CKD, number of haemodialysis sessions, and blood parameters.
The hearing thresholds at low and high frequency ranges were compared between these groups to identify the pattern of hearing loss. Written informed consent was obtained from CKD patients and controls. Approval of the Institute Ethics and Research Committee was obtained prior to the study.
Statistical methods
In order to estimate a prevalence of 50 per cent with 9 per cent precision, a sample size of 119 was required, hence we included 120 subjects in each group. Prevalence and degree of sensorineural hearing loss was determined using descriptive statistics (mean, median, and standard deviation). CKD patients with and without hearing loss were compared using unpaired t-test for normally distributed variables and Mann Whitney test for non-normally distributed variables. Chi-square test was used to determine association between variables. Differences were considered significant if the p value was less than 0.05.
Results
The majority of patients in both CKD and control groups were male (75.8 per cent). Prevalence of diabetes and hypertension were higher in CKD patients, whereas there was no significant difference in the prevalence of hypothyroidism between CKD patients and controls (Table  1) .
Overall, hearing loss as established by pure tone average was present in 50 out of 120 (41.7 per cent) CKD patients and 18 out of 120 (15 per cent) controls (p=0.001). Hearing thresholds were abnormal at low frequencies (250 Hz to 1 kHz) in 33 (27.5 per cent) patients and at high frequencies (2 kHz to 8 kHz) in 93 (77.5 per cent) CKD patients. Hearing thresholds were abnormal across all frequency ranges in 52 (43 per cent) CKD patients. Thus, high-frequency hearing loss was the most common hearing impairment among CKD patients, followed by hearing impairment across all frequencies and low-frequency hearing loss. Sensorineural hearing loss was mild in the majority of CKD patients. There was significant difference between CKD patients and controls across all degrees of hearing loss (Table 2) . Of the 50 CKD patients with hearing loss, 38 had bilateral hearing loss, although this was not symmetric. In the control group, of the 18 subjects with hearing loss, 9 had bilateral impairment. The difference was not significant (p=0.07).
Comparison of CKD patients with and without hearing loss
The mean age of CKD patients with hearing loss was 52.7 years (SD=10.9) compared to 47 years (SD=12) among CKD patients without hearing loss (p=0.04). Thus CKD patients with hearing loss were a little older than those without hearing loss.
Twenty-five (50 per cent) of CKD patients with hearing loss had received ototoxic drugs compared to 21 out of 70 (30 per cent) of CKD patients without hearing loss (p=0.04).
Frusemide was the most commonly implicated ototoxic drug. History of noise exposure, prevalence of diabetes, hypertension, and hypothyroidism, and mean values of blood parameters like haemoglobin, renal function, and electrolytes were comparable between the two groups (Table 3) . The majority of CKD patients with hearing loss had disease duration between seven months to three years ( Figure 1 ). The median duration of disease in CKD patients with and without hearing loss was 18 months (p=0.62). Thus, duration of CKD had no association with hearing loss.
Figure 1: Duration of disease among CKD patients with hearing loss
Among CKD patients with hearing loss, the majority received 250 or fewer haemodialysis sessions ( Figure 2 ). The median number of haemodialysis sessions was significantly more in CKD patients without hearing loss (122 vs. 72, p=0.04).
Figure 2: Number of haemodialysis sessions in CKD patients with hearing loss
Comparison of pure tone thresholds between CKD patients with and without hearing loss revealed that hearing loss was significant at low as well as high frequencies (Table 4) . 
Discussion
This study found that 41.7 per cent of CKD patients on haemodialysis had hearing loss, considerably higher than the normal population. In other words, every second or third CKD patient on haemodialysis experiences some degree of hearing impairment. The majority of these patients experienced mild hearing loss. Hearing thresholds were abnormal in CKD patients on haemodialysis across all frequencies ranging from 250Hz to 8 kHz. This study also showed that CKD patients with hearing loss received significantly fewer haemodialysis sessions compared to those without hearing loss. About one-half of CKD patients with hearing loss in our study had received ototoxic medications compared to one-third of CKD patients without hearing loss, suggesting a contributory role for ototoxic drugs in genesis of hearing loss in these patients.
The prevalence of hearing loss in CKD patients varies from 28 per cent to 77 per cent according to different studies. 10, 11 Notably, many older studies have shown higher prevalence of hearing loss, possibly due to small sample sizes. Hearing thresholds were abnormal at high frequencies in 77.5 per cent of CKD patients and at low frequencies in 27.5 per cent in our study. This is in contrast to the study by Gatland et al. who found 41 per cent hearing impairment in low frequencies and 53 per cent in high frequency range. 12 Moreover, Qin and Gurbanov reported that the characteristic of hearing loss in CKD patients is high frequency abnormality. 13, 14 We also observed that hearing loss at high frequencies might be the most common audiometric abnormality in CKD patients, but not the typical one. This difference may be due to several reasons. First, the sample sizes in both studies were small (49 and 63 CKD patients, respectively). Second, Qin used high-frequency audiometry to assess the patients, possibly identifying patients with even mild abnormalities at higher frequencies not employed in conventional audiometry. Third, most of Gurbanov's subjects had endstage renal disease, precluding generalisation of results to all CKD patients. In line with most previous studies, we too were unable to demonstrate any association between duration of CKD and hearing loss. The main limitation of this study was the cross-sectional observational design. We were not able to assess causation, although we found associations between hearing loss in CKD and several factors. However, the advantage offered by the large sample size (both CKD patients and controls) must be mentioned as its greatest strength.
This study, apart from its preliminary findings, also reveals the lacunae in our current understanding of hearing loss in CKD. Although there exists no further doubt that hearing loss is prevalent among CKD patients, well-designed studies with larger sample sizes are needed to elucidate the causal relationships between hearing loss in CKD and haemodialysis. Another logical question that arises in this context is whether a blanket audiometric screening of all CKD patients would help identify mild hearing loss and prevent progression to severe degrees, especially if a beneficial role for haemodialysis can be definitely established in long-term prospective studies. Besides, the association of hearing loss in CKD and ototoxic drugs needs to be addressed by more research as this could have significant implications for clinical practice
Conclusion
A mild degree of sensorineural hearing loss is quite common in CKD patients undergoing haemodialysis. Hearing loss in CKD patients does not follow any specific pattern and prevails at high and low frequencies. These patients are likely to be older and have a significantly greater exposure to ototoxic drugs. Duration of disease is not associated with hearing loss in CKD patients undergoing haemodialysis. However, haemodialysis may have an ameliorative effect on hearing loss in CKD, an association that needs to be tested further by long-term prospective studies.
